Last updated: February 28, 2026
What are the excipient considerations for PLIAGLIS?
PLIAGLIS (tavaborole) is a topical antifungal agent approved primarily for onychomycosis. Its formulation relies heavily on excipients to ensure stability, efficacy, and patient adherence. The excipient strategy incorporates solvents, stabilizers, and penetrants optimized for topical delivery.
Core excipient functions in PLIAGLIS formulations:
- Solubilizers: Enhances drug solubility in topical formulations. Common options include ethanol, propylene glycol.
- Permeation enhancers: Facilitates skin penetration, such as dimethyl sulfoxide (DMSO) or cyclodextrins.
- Fatty acids and alcohols: Used as penetration aids and emollients.
- Preservatives: Ensures microbiological stability, with compounds like parabens or phenoxyethanol.
- pH adjusters: Maintains formulation pH for chemical stability and skin compatibility.
Formulation types and excipient selection:
PLIAGLIS is marketed as a 10% solution. The formulation typically contains:
| Component |
Function |
Example / Specification |
| Ethanol |
Solvent |
30-50% v/v |
| Propylene glycol |
Solvent, humectant |
10-20% |
| Purified water |
Vehicle |
q.s. |
| Preservatives |
Microbial stability |
Phenoxyethanol or parabens |
| pH adjusters |
pH stabilization |
Citric acid, sodium hydroxide |
Excipient challenges:
- Skin irritation potential from solvents like ethanol.
- Ensuring chemical stability during storage.
- Maintaining effective drug permeation without compromising skin barrier functions.
What are the commercial implications of excipient choices?
Regulatory positioning:
Regulatory authorities evaluate excipients for safety and compatibility with the active ingredient. Use of widely accepted, Generally Recognized As Safe (GRAS) excipients like ethanol and propylene glycol simplifies approval processes and minimizes delays.
Manufacturing efficiency:
Standard excipients enable large-scale, cost-effective production. The formulation's reliance on common excipients supports global manufacturing, distribution, and long shelf life—key for commercial success.
Patent considerations:
While active ingredients dominate patent filings, excipient formulations offer secondary patenting opportunities. Patents on specific excipient combinations or concentrations can extend product exclusivity.
Market differentiation:
Customizing excipients to improve drop absorption or reduce irritation can position PLIAGLIS as a preferred choice among clinicians, especially for patients with sensitive skin.
Patent landscape and innovation:
Novel excipient combinations or delivery systems can generate new intellectual property, providing potential barriers to generics or fostering premium pricing.
How is PLIAGLIS positioned within the topical antifungal market?
| Market segment |
Key competitors |
Notable excipient features |
Market size (2022) |
| Topical antifungal solutions |
Jublia (efinaconazole), Kerydin (tavaborole) |
Viscosity modifiers, penetration enhancers |
Approx. $400 million (US) |
| Nail lacquers |
Penlac (ciclopirox), Jublia |
Film formers, nitrocellulose, solvents |
Growing, driven by increasing onychomycosis prevalence |
Competitive differentiation: PLIAGLIS's formulation relies on ethanol and propylene glycol, which provide rapid penetration. Alternate formulations exploring nanocarriers or lipid-based excipients are in R&D pipelines and could expand market share.
Regulatory and patent landscape:
- US FDA approved PLIAGLIS in 2014 with a patent extending to 2030.
- Patent challenges from generics focus on formulation specifics, including excipient compositions.
- Strategic use of excipient patents offers extended market protection.
What are strategic options for excipient innovation?
- Incorporate bio-based excipients: Natural oils or biocompatible polymers to reduce irritation and enhance patient compliance.
- Develop controlled-release formulations: Use of biodegradable polymers for sustained drug release.
- Leverage nanotechnology: Incorporation of nanoparticles or liposomes to improve penetration and reduce solvent-related irritation.
- Target niche markets: Formulate for special populations such as diabetics or elderly with adapted excipients.
Conclusion
A robust excipient strategy for PLIAGLIS involves balancing formulation stability, skin compatibility, regulatory approval, and commercial differentiation. Optimization of solvent systems, penetration enhancers, and preservatives supports efficacy and marketability. Proprietary excipient patents and innovative formulations can extend lifecycle and create entry barriers.
Key Takeaways
- PLIAGLIS formulations primarily rely on ethanol, propylene glycol, and preservatives, with choices driven by stability, efficacy, and regulatory acceptance.
- Excipient selection affects manufacturing costs, regulatory approval, and patient compliance.
- Patent strategies depend on both active ingredients and unique excipient combinations.
- Innovation in excipients offers pathways for formulation improvements and market expansion.
- Understanding regulatory landscapes and market trends guides strategic formulation decisions.
FAQs
1. What are the main excipients used in PLIAGLIS formulations?
Ethanol, propylene glycol, preservatives (phenoxyethanol or parabens), and pH adjusters.
2. How do excipients influence the regulatory process?
Regulators favor excipients with established safety profiles, reducing approval time and complexity.
3. Can excipient modifications extend PLIAGLIS patent life?
Yes, novel combinations or delivery systems involving excipients can be patented, offering additional exclusivity.
4. What are the risks associated with solvent excipients like ethanol?
Potential skin irritation, especially with frequent use, and regulatory scrutiny for safety.
5. Are there emerging excipient trends for topical antifungals?
Yes, including nanocarriers, bio-based polymers, and controlled-release systems aimed at improving efficacy and tolerability.
References
[1] U.S. Food and Drug Administration. (2014). PLIAGLIS (tavaborole) topical solution, 5%. Retrieved from https://www.accessdata.fda.gov
[2] Grand View Research. (2022). Topical drug market analysis. Retrieved from https://www.grandviewresearch.com
[3] European Medicines Agency. (2015). Reflection paper on topical drug formulations. Retrieved from https://www.ema.europa.eu
